Decitabine-based chemotherapy followed by haploidentical lymphocyte infusion improves the effectiveness in elderly patients with acute myeloid leukemia

作者：Jing, Yu; Jin, Xiangshu; Wang, Lixin; Dou, Liping; Wang, Quanshun; Yao, Yushi; Lian, Shimei; Zhou, Jihao; Zhu, Haiyan; Yao, Zilong; Gao, Lijun; Wang, Lili; Li, Yonghui; Bai, Xuefeng; Fang, Meiyun^*; Yu, Li^*

来源：Oncotarget, 2017, 8(32): 53654-53663.

DOI：10.18632/oncotarget.11183

• decitabine
• haploidentical lymphocyte infusion
• Induction therapy
• acute myeloid leukemia

In this study, we first initiated a multicenter, single-arm, phase-II clinical trial using decitabine (DAC) (20mg/m(2) for five days) based chemotherapy, followed by haploidentical lymphocyte infusion (HLI) that was applied as induction therapy for elderly patients with AML. Furthermore, the role of HLI infusion was explored in a mouse model. The clinical trial included 29 elderly patients (median age: 64, range 5777) with AML. Sixteen cases achieved complete remission (CR) and 9 cases achieved partial remission (PR) after the first treatment cycle. Of the patients with PR, 5 subjects achieved remission after the second induction, which brings the overall CR rate to 72.4%. The 2-year overall survival (OS) and disease-free survival (DFS) was 59.6% and 36.9% respectively. The treatment regimen was well tolerated with only one patient died of severe pneumonia one month after the first treatment. In the mouse experiment, we found that DAC/HLI significantly enhanced the survival of leukemic mice. These results suggested that DAC-based chemotherapy combined with HLI is an alternative first line induction therapy for elderly patients with AML.

• 出版日期2017-8-8
• 单位大连市中心医院; 大连医科大学; 中国人民解放军总医院; 中国人民解放军海军总医院